Retrospective Analysis of Clinicoepidemiological Factors and Outcome in Pancreatic Cancer
Muhammad Ali Ibrahim Ahmed Heiba;
Abstract
SUMMARY
P
ancreatic cancer is a very aggressive disease, and the fact that its incidence rates are almost equal to its mortality rates highlights its lethality.
Surgery provides at present the only potentially curative treatment for pancreatic cancer; however most patients are diagnosed at an advanced stage, which makes surgery difficult and ineffective, and only 10 to 20% of patients are able to undergo curative resection.
Adjuvant chemotherapy have shown benefit to improve cure rates, however the role of radiotherapy remains controversial, and there is no consensus regarding the optimal management of patients following resection of pancreatic cancer.
When patients are not candidates for surgery, systemic chemotherapy and radiotherapy are used in the treatment of locally unresectable and metastatic pancreatic cancer only palliative to improve quality of life. However, systemic chemotherapy for pancreatic cancer has proven of limited value because of the low response rates and the severe adverse effects.
Studies in first-line treatment of metastatic and locally advanced disease have shown an improved survival from both FOLFIRINOX and a combination of gemcitabine and nab-paclitaxel vs. the previous standard of care, gemcitabine
In the light of such poor results, analyzing prognostic factors which may influence the outcome is necessary in order to individualize treatment options for pancreatic cancer patients.
Several studies have reported various prognostic factors as determinants of survival. Our study analyzed several epidemiological, pathological and clinical factors to determine their role in predicting the outcome for pancreatic cancer patients.
Our analysis showed that tumor size, tumor site, stage, performance status, resection margin, lymph node status, post-operative CA19-9 level, WBC count and bilirubin level are prognostic indicators for survival and should be assessed in the initial workup of pancreatic cancer patients
More prospective trials are needed to further evaluate the influence of these factors, and their impact on determining treatment options.
P
ancreatic cancer is a very aggressive disease, and the fact that its incidence rates are almost equal to its mortality rates highlights its lethality.
Surgery provides at present the only potentially curative treatment for pancreatic cancer; however most patients are diagnosed at an advanced stage, which makes surgery difficult and ineffective, and only 10 to 20% of patients are able to undergo curative resection.
Adjuvant chemotherapy have shown benefit to improve cure rates, however the role of radiotherapy remains controversial, and there is no consensus regarding the optimal management of patients following resection of pancreatic cancer.
When patients are not candidates for surgery, systemic chemotherapy and radiotherapy are used in the treatment of locally unresectable and metastatic pancreatic cancer only palliative to improve quality of life. However, systemic chemotherapy for pancreatic cancer has proven of limited value because of the low response rates and the severe adverse effects.
Studies in first-line treatment of metastatic and locally advanced disease have shown an improved survival from both FOLFIRINOX and a combination of gemcitabine and nab-paclitaxel vs. the previous standard of care, gemcitabine
In the light of such poor results, analyzing prognostic factors which may influence the outcome is necessary in order to individualize treatment options for pancreatic cancer patients.
Several studies have reported various prognostic factors as determinants of survival. Our study analyzed several epidemiological, pathological and clinical factors to determine their role in predicting the outcome for pancreatic cancer patients.
Our analysis showed that tumor size, tumor site, stage, performance status, resection margin, lymph node status, post-operative CA19-9 level, WBC count and bilirubin level are prognostic indicators for survival and should be assessed in the initial workup of pancreatic cancer patients
More prospective trials are needed to further evaluate the influence of these factors, and their impact on determining treatment options.
Other data
| Title | Retrospective Analysis of Clinicoepidemiological Factors and Outcome in Pancreatic Cancer | Other Titles | دراسة ارتجاعية عن العوامل الاكلينيكية الوبائية و تأثيرها في نتائج حالات أورام البنكرياس | Authors | Muhammad Ali Ibrahim Ahmed Heiba | Issue Date | 2017 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.